Innovative Aerosolized virus technique testing any drug, disinfectant and sanitizing device against respiratory viruses (e.g. SARS-CoV-2 and influenza) mimicking virus’ natural transmission milieu

Short summary Respiratory infections are the leading cause of death among infectious diseases. SARS-CoV, MERS-CoV, influenza, and the rhinoviruses that cause the common cold, all spread via aerosols that can build up in indoor air and linger for hours. An Italian innovative SME has built up and finely tuned an aerosol system allowing the testing of any disinfectant, device, small molecule and chemical or natural compound ,for efficacy against a respiratory virus mimicking its natural transmission milieu.

Full description The Company, a privately held bio-pharmaceutical company headquartered in Italy, is an independent contract testing laboratory specialized in the analysis of any substance (drug, biological, natural plant extract, etc.) in appropriate cell systems in vitro to determine its efficacy against respiratory viruses (any variant), Influenza virus and other respiratory viruses, by employing virus in suspension, in aerosol or on textile and porous material. The Company is also equipped to test any type of device (such as ozone-based machines, U.V. lamps, filtering machines, electromagnetic wave emitters) against respiratory viruses, both in liquid suspension and in different aerosol experimental setups, tailored to customer’s needs. The Company’s team has many years of experience in the field of infectious diseases ensuring the Company’s methods and testing services meet the highest level of scrutiny under complex quality control and regulatory requirements, in compliance with the guidelines for handling the virus in highly biological containment laboratories (BSL3), according to European standards EN14476: 2013 + A2: 2019. The Company provides a full range of laboratory assays needed to achieve research goals for a broad range of applications including tailored cytotoxicity, activity and immunologic assays, assuring robust processes to generate high-quality data. Methodology: • Cytotoxicity of test materials will be determined through standard MTS assay or equivalent in Vero E6. Different concentrations of test substances will be evaluated in order to determine a CC50 (cytotoxic concentration 50%) • Efficacy against new coronavirus strain will be determined in infected cells by testing different concentrations of the test materials • Viral replication will be measured by ELISA assay or cytoprotection assay and an IC50 (inhibitory concentration 50%) will be determined

Advantages and innovations Use of real life viruses, not surrogate viruses Customized and validated assays based on Clients’ needs Reproducibility of the results Robust processes to generate high quality data High Quality testing solutions and fast answers Innovative technology that mimics the virus natural transmission milieu
Contact / source: NEXT EEN Widgets (europa.eu)